Overview
Based on the shared priorities of BioCanRx and the Cancer Stakeholder Alliance, the Joint Action Plan outlines the objectives and activities for the BioCanRx Cancer Stakeholder Alliance Working Group. The overall goals of the Joint Action Plan are to help ensure
- The inclusion of the experience and perspective of cancer patients, their families and the concerned public in BioCanRx activities and projects; and
- The accessibility of BioCanRx research information.
In 2017, BioCanRx partnered with the Cancer Stakeholder Alliance Working Group to execute its Cycle 1 Joint Action Plan and will continue to do so in Cycle 2 to carry out the 2020-2023 Joint Action Plan.
The priorities of the Joint Action Plan are identified by the Cancer Stakeholder Alliance and are also based on the Terms of Reference of the Cancer Stakeholder Alliance and Cancer Stakeholder Alliance Working Group.
See below for additional information on the current (Cycle 2) and past (Cycle 1) BioCanRx Cancer Stakeholder Alliance Joint Action Plans:
Contact
For more information about the BioCanRx Stakeholder Alliance Joint Action Plan, please contact Stéphanie Michaud, by email (smichaud@biocanrx.com).
Joint Action Plans
The BioCanRx Stakeholder Alliance Joint Action Plan of the Cancer Stakeholder Alliance Working Group was launched late in January 2021 due to COVID-19. The Joint Action Plan for 2020-2023 is based on the same priorities as identified by the Cancer Stakeholder Alliance in 2017, which were confirmed by the Cancer Stakeholder Alliance in May 2019:
- Patient Clinical Trial Information
- The Learning Institute
- Patient Perspective in Research
Outcomes from Cycle 1 (2017-2020) CSA Joint Action Plan include:
- Developed plain language summary Fact Sheets for BioCanRx Cycle 1 Clinical Trials (8)
- Developed a Clinical Trial map for BioCanRx trials
- Conducted survey for feedback on CT map through CSA membership and incorporated feedback
Action items for the Cycle 2 (2020-2023) Plan:
- Establishment of guidelines and best practices for the development of plain language summary Fact Sheets for all BioCanRx funded projects to make them more comprehensible and accessible for patients.
- Explore the potential of sharing the best practices & guidelines for plain language summary fact sheets beyond BioCanRx.
- Increased views and usage of BioCanRx plain language summary Clinical Trial Fact Sheets
Priority: The Learning Institute
Outcomes from Cycle 1 (2017-2020) CSA Joint Action Plan include:
- Established the framework for BioCanRx’s Learning Institute (LI)
- Held successful LIs at the 2017, 2018 and 2019 Summits for Cancer Immunotherapy
- Trained 28 patient scholars during Cycle 1
Action items for the Cycle 2 (2020-2023) Plan:
- Hold successful Learning Institutes at the 2022 and 2023 Summits for Cancer Immunotherapy (Summit4CI).
- Explore the establishment of a shared model of the LI with a sustainable funding model, to expand its usage beyond BioCanRx.
- Develop a plan for a virtual LI
Priority: Patient Engagement in Research
Outcomes from Cycle 1 (2017-2020) CSA Joint Action Plan include:
- Patient-Researcher roundtables were held at Summit4CI in 2018 and 2019 stressing the importance of integration of the patient perspective in the planning and implementation of research projects.
- Established a searchable BioCanRx Network Investigator database.
Action items for the Cycle 2 (2020-2023) Plan:
- Hold sessions encouraging patient engagement in research at the 2021, 2022 and 2023 Summits for Cancer Immunotherapy.
- Establish a Patient Scholar Database for the use of researchers to increase patient engagement in BioCanRx-funded research.
- Provide accessible tools to support the process of engagement of patients in the research process.
